[Asia Economy Reporter Hyunseok Yoo] Egix is showing strong performance. It is interpreted that the news that Immunomic Therapeutics (hereinafter Immunomic), a U.S. vaccine development company in which $10 million was invested last April, confirmed seven times higher efficacy compared to existing treatments in clinical trials of glioblastoma dendritic cell vaccines had an impact.
As of 12:41 PM on the 2nd, Egix was traded at 1,620 KRW, up 6.93% (105 KRW) from the previous trading day.
On the same day, HL Biopharma announced that while the 5-year survival rate for glioblastoma patients with existing treatments is 5%, patients who received Immunomic’s vaccine ‘ITI-1000’ showed a survival rate of about 35%. John Sampson, a brain tumor treatment expert at Duke University who conducted the clinical trial, stated, “Glioblastoma is a very aggressive cancer and a very difficult disease to treat, but these clinical results are very encouraging.”
Meanwhile, Egix made an investment in Immunomic as a friendly shareholder of HL Biopharma. Including HL Biopharma’s 38.16% stake in Immunomic, they plan to expand their stake in Immunomic to 51% and aim to list on the NASDAQ or KOSDAQ market.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
